Skip to main content

Table 4 Oral antidiabetic drug use before insulin initiation, at insulin initiation, and at 1-year follow-up

From: Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study

Oral antidiabetic drug Before insulin initiation (N = 511) At insulin initiation (N = 511) 1-year follow-up (N = 488)
No. of oral antidiabetic drugs, n (%)    
  0 98 (19.2%) 262 (51.3%) 229 (46.9%)
  1 119 (23.3%) 110 (21.5%) 127 (26.0%)
  2 170 (33.3%) 91 (17.8%) 94 (19.3%)
  ≥3 124 (24.3%) 48 (9.4%) 38 (7.8%)
Drug class, n (%)    
  Biguanides 148 (29.0%) 109 (21.3%) 120 (24.6%)
  Sulfonylureas 357 (69.9%) 133 (26.0%) 99 (20.3%)
  Glinides 28 (5.5%) 10 (2.0%) 78 (16.0%)
  Thiazolidinediones 134 (26.2%) 80 (15.7%) 36 (7.4%)
  α-glucosidase inhibitor 177 (34.6%) 107 (20.9%) 104 (21.3%)
  Others 5 (1.0%) 5 (1.0%) 0